When NEXT Life Sciences acquired the male contraceptive product, Vasalgel, they sought the right group to help develop a strategy for the rollout in this sensitive and potentially controversial space. CWJ Strategies came on board to assist the start-up with the right message to position Vasalgel for success. Using the heightened focus on reproductive rights following the reversal of Roe vs. Wade, CWJ Strategies created a campaign to help normalize discussion of male contraceptive use, attaining the goal of de-risking the product and securing opportunities for NEXT to discuss Vasalgel with journalists in the medical technology arena.
